BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23085037)

  • 1. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
    Kao SC; Lee K; Klebe S; Henderson D; McCaughan B; Vardy J; Clarke S; van Zandwijk N
    Clin Lung Cancer; 2013 Mar; 14(2):164-71. PubMed ID: 23085037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
    Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
    J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
    Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
    Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
    J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
    Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
    J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
    Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
    Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
    Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
    Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Richards WG; Sugarbaker DJ
    Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
    Mineo TC; Ambrogi V; Pompeo E; Baldi A; Stella F; Aurea P; Marino M
    Ann Thorac Surg; 2008 May; 85(5):1740-6. PubMed ID: 18442576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
    Rena O; Casadio C
    Lung Cancer; 2012 Jul; 77(1):151-5. PubMed ID: 22244608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
    Yan TD; Boyer M; Tin MM; Wong D; Kennedy C; McLean J; Bannon PG; McCaughan BC
    J Thorac Cardiovasc Surg; 2009 Sep; 138(3):619-24. PubMed ID: 19698846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extrapleural pneumonectomy for malignant pleural mesothelioma].
    Morohoshi T; Yamamoto T; Nagashima T
    Kyobu Geka; 2007 Jan; 60(1):40-4. PubMed ID: 17249537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
    Sharif S; Zahid I; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 Jun; 12(6):1040-5. PubMed ID: 21388982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extrapleural pneumonectomy for malignant pleural mesothelioma].
    Hosokawa Y; Matsuge S; Hayashi K; Kawahara Y; Ishigooka M; Kan T; Yamaawa T; Hatakeyama H; Murakami Y
    Kyobu Geka; 2004 Oct; 57(11):1018-22. PubMed ID: 15510814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
    Sugarbaker DJ; Wolf AS; Chirieac LR; Godleski JJ; Tilleman TR; Jaklitsch MT; Bueno R; Richards WG
    Eur J Cardiothorac Surg; 2011 Aug; 40(2):298-303. PubMed ID: 21310625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
    Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
    Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical surgery for malignant pleural mesothelioma: results and prognosis.
    Okada M; Mimura T; Ohbayashi C; Sakuma T; Soejima T; Tsubota N
    Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):102-6. PubMed ID: 18048410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.